Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Human Growth Hormone in Transgenesis: A Growing Problem?

  1. Bas Brouwers and
  2. John W.M. Creemers⇑
  1. Laboratory for Biochemical Neuroendocrinology, KU Leuven, Leuven, Belgium
  1. Corresponding author: John W.M. Creemers, john.creemers{at}med.kuleuven.be.
Diabetes 2015 Nov; 64(11): 3648-3650. https://doi.org/10.2337/dbi15-0007
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Temporospacial overexpression or inactivation of genes in mouse models has undeniably boosted biomedical research. This is most commonly achieved using the Cre-loxP technique, where mice expressing Cre recombinase driven by a tissue-specific or inducible promoter are bred with mice in which one or more exons of a gene of interest are flanked by LoxP sites (1). This allows for a more in-depth view of the gene function in the context of a particular time frame and tissue system, while avoiding unwanted effects due to the absence of this gene during development.

However, in the recent years several pitfalls have emerged related to this technique (2–4). There have been reports of disturbed endogenous gene expression at the site of the Cre-transgene insertion (4), low or mosaic Cre expression (5,6), and expression in undesired tissues, such as unwanted Cre activity in nutrient-sensing neurons from transgenic mice that express Cre under the control of Ins2 and Pdx1 promoters (7,8). Equally disturbing is the finding that high Cre activity can cause chromosomal rearrangements, apoptosis, and decreased proliferation (9–11). Particularly for diabetes and central nervous system research, these caveats have been reviewed in detail (2,3).

In this issue of Diabetes, Oropeza et al. (12) describe yet another concern in the tamoxifen-inducible MIP-CreERT1Lphi mouse line caused by transgenic human growth hormone (hGH) expression. In the 1980s, a pioneering study described that the presence of introns induces more efficient transgene expression (13). Soon after, this principle was demonstrated using heterologous introns in animals (14). In the early 1990s, the entire hGH gene was inserted downstream of the Cre fragment as a transgene enhancer (15) and has become a routine strategy ever since. Recently, however, it has been shown that this can result in a bicistronic Cre-hGH mRNA. As a result, the mRNA is translated not only in Cre recombinase but also in functional hGH (16,17). Interestingly, hGH can activate both the growth hormone receptor and the prolactin receptor (PRLR) (17,18). Particularly on β-cells, hGH acts as a lactogen and binds to the PRLR present on β-cells, hereby inducing pregnancy-related changes, such as an increase in β-cell mass and insulin content, induction of serotonin synthesis, and protection against the β-cell toxin streptozotocin (STZ). Next to a pregnancy phenotype, impaired glucose-stimulated insulin secretion and decreased β-cell GLUT2 levels were observed.

The MIP-CreERT1Lphi mouse line was welcomed in the field as it was the first that used an 8.5-kb fragment of the mouse Ins1 promoter, driving Cre activity exclusively to β-cells while being absent in the brain (7). In addition, no adverse effects on glucose tolerance and glucose-stimulated Ca2+ release were observed (19). However, Oropeza et al. (12) provide a more extensive and detailed analysis of this mouse model. First, strong evidence is provided using higher resolution techniques and the mT/mG reporter line (20) that Cre activity is indeed exclusively found in β-cells and not in hypothalamic or hindbrain nuclei, as was reported before in other strains (7,8). Furthermore, whole-body glucose homeostasis was similar to controls, both on normal chow and after a high-fat, high-sucrose (HFHS) diet. However, they observed that despite secreting normal amounts of insulin upon in vitro glucose stimulation there was an increase in pancreatic islet number and insulin content. Strikingly, MIP-CreERT animals on both C57BL/6 and FVB backgrounds were strongly protected against the type 2 diabetes–inducing HFHS/STZ regimen. Significant resistance was also seen for single high-dose STZ administration. Similar to the previously reported strains (17), MIP-CreERT mice express high levels of hGH in islets, independent of tamoxifen administration. After autocrine/paracrine activation of the PRLR, this results in Tryptophan hydroxylase-1 (Tph1) and -2 (Tph2) expression, which in turn induces serotonin biosynthesis. Finally, the authors provide evidence that serotonin negatively affects compensatory α-cell proliferation and glucagon secretion upon HFHS/STZ in this mouse line (Fig. 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

MIP-CreERT mice express high levels of bioactive hGH in pancreatic β-cells. This activates the prolactin receptor, which induces serotonin biosynthesis and causes protection against HFHS/STZ. β-Cell serotonin has a paracrine effect on pancreatic α-cells, negatively influencing α-cell number and glucagon secretion (12).

Interestingly, Oropeza et al. (12) did not observe impaired glucose-stimulated insulin secretion and decreased GLUT2 levels as was shown before in the Pdx1-CreLate model that also expresses hGH in islets (17). This suggests that these impairments are independent of hGH bioactivity. Another explanation could be a gene-dose response of hGH in different lines, as the levels of hGH protein could depend on the promoter type, insertion site, and the mouse strain, as suggested previously (21). Adding quantification of absolute islet hGH levels by ELISA or high-performance liquid chromatography would allow a direct comparison of hGH levels between mouse strains. Next to islets, lower hGH mRNA levels were also detected in the arcuate nucleus and ventromedial hypothalamus, but the question remains as to whether this has considerable effects on physiology. For example, whole-genome expression profiling on these microdissected hypothalamic regions could possibly address this issue. Finally, this study is the first to demonstrate additional transgene-related effects on pancreatic α-cells. Whether this phenomenon also occurs in other pancreatic driver lines expressing hGH could be the subject of future research.

Reports such as this are crucial to help move the field forward. The hGH minigene has been used as a transgene enhancer since the beginning of conditional mouse targeting, extending into various research areas, with a total number of lines exceeding well over 200 (G. de Faudeur, B. Ramos-Molina, B.B., F. Schuit, J.W.M.C., unpublished data). In several lines, bioactive hGH has now been demonstrated in islets, the pituitary, and the hypothalamus. On the other hand, no hGH protein was found in the liver, despite high levels of Cre-hGH mRNA (16). The reason for this tissue-dependent translation is unknown. Validating each line in great detail, such as the MIP-CreERT line, is therefore key to the design of future experiments as well as for the careful reinterpretation of published work.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 3798.

  • © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Sauer B,
    2. Henderson N
    . Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 1988;85:5166–5170pmid:2839833
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Harno E,
    2. Cottrell EC,
    3. White A
    . Metabolic pitfalls of CNS Cre-based technology. Cell Metab 2013;18:21–28pmid:23823475
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Magnuson MA,
    2. Osipovich AB
    . Pancreas-specific Cre driver lines and considerations for their prudent use. Cell Metab 2013;18:9–20pmid:23823474
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Schmidt-Supprian M,
    2. Rajewsky K
    . Vagaries of conditional gene targeting. Nat Immunol 2007;8:665–668pmid:17579640
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Gannon M, Herrera PL, Wright CV Mosaic Cre-mediated recombination in pancreas using the pdx-1 enhancer/promoter. Genesis 2000;26:143–144
  6. ↵
    1. Ryding AD,
    2. Sharp MG,
    3. Mullins JJ
    . Conditional transgenic technologies. J Endocrinol 2001;171:1–14pmid:11572785
    OpenUrlAbstract
  7. ↵
    1. Wicksteed B,
    2. Brissova M,
    3. Yan W, et al
    . Conditional gene targeting in mouse pancreatic β-cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 2010;59:3090–3098pmid:20802254
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Song J, Xu Y, Hu X, Choi B, Tong Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis 2010;48:628–634
  9. ↵
    1. Schmidt EE,
    2. Taylor DS,
    3. Prigge JR,
    4. Barnett S,
    5. Capecchi MR
    . Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. Proc Natl Acad Sci U S A 2000;97:13702–13707pmid:11087830
    OpenUrlAbstract/FREE Full Text
    1. Loonstra A,
    2. Vooijs M,
    3. Beverloo HB, et al
    . Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A 2001;98:9209–9214pmid:11481484
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Naiche LA,
    2. Papaioannou VE
    . Cre activity causes widespread apoptosis and lethal anemia during embryonic development. Genesis 2007;45:768–775pmid:18064676
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Oropeza D, Jouvet N, Budry L, et al. Phenotypic characterization of MIP-CreERT1Lphi mice with transgene-driven islet expression of human growth hormone. Diabetes 2015;64:3798–3807
  12. ↵
    1. Brinster RL,
    2. Allen JM,
    3. Behringer RR,
    4. Gelinas RE,
    5. Palmiter RD
    . Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci U S A 1988;85:836–840pmid:3422466
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Palmiter RD,
    2. Sandgren EP,
    3. Avarbock MR,
    4. Allen DD,
    5. Brinster RL
    . Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A 1991;88:478–482pmid:1988947
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Orban PC,
    2. Chui D,
    3. Marth JD
    . Tissue- and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci U S A 1992;89:6861–6865pmid:1495975
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Pruniau VPEG, Louagie E, Brouwers B, Declercq J, Creemers JW. The AlfpCre mouse revisited: evidence for liver steatosis related to growth hormone deficiency. Hepatology 2013;58:2209–2210
  16. ↵
    1. Brouwers B,
    2. de Faudeur G,
    3. Osipovich AB, et al
    . Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab 2014;20:979–990pmid:25470546
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Wolf E,
    2. Rapp K,
    3. Brem G
    . Expression of metallothionein-human growth hormone fusion genes in transgenic mice results in disproportionate skeletal gigantism. Growth Dev Aging 1991;55:117–127pmid:1938045
    OpenUrlPubMed
  18. ↵
    1. Tamarina NA,
    2. Roe MW,
    3. Philipson L
    . Characterization of mice expressing Ins1 gene promoter driven CreERT recombinase for conditional gene deletion in pancreatic β-cells. Islets 2014;6:e27685pmid:25483876
    OpenUrlCrossRefPubMed
  19. ↵
    1. Muzumdar MD,
    2. Tasic B,
    3. Miyamichi K,
    4. Li L,
    5. Luo L
    . A global double-fluorescent Cre reporter mouse. Genesis 2007;45:593–605pmid:17868096
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Estall JL,
    2. Screaton RA
    . To be(ta cell) or not to be(ta cell): new mouse models for studying gene function in the pancreatic β-cell. Endocrinology 2015;156:2365–2367pmid:26091426
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes: 64 (11)

In this Issue

November 2015, 64(11)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human Growth Hormone in Transgenesis: A Growing Problem?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human Growth Hormone in Transgenesis: A Growing Problem?
Bas Brouwers, John W.M. Creemers
Diabetes Nov 2015, 64 (11) 3648-3650; DOI: 10.2337/dbi15-0007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Human Growth Hormone in Transgenesis: A Growing Problem?
Bas Brouwers, John W.M. Creemers
Diabetes Nov 2015, 64 (11) 3648-3650; DOI: 10.2337/dbi15-0007
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.